Innovating the next generation of immunological therapeutics

Key Opinion Leaders

TLA was systematically introduced to Key Opinion Leaders through an independent survey by Horizon Research and Consulting in the US, UK, Spain, Germany, and Japan. 

The survey yielded an overall very positive response summarised in the figure below.

Note: KOL support is expected to be even higher since the survey was conducted before the successful proof-of-concept Phase I/II clinical trial was finalised.